RxDoctor Payments Data

Brett Nile, MD

Family Medicine · San Angelo, TXNPI 1154322014

Payments from drug & device makers

$10,790in general payments, 2019–2025

Across 535 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Biohaven Pharmaceuticals, Inc.$2K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Boehringer Ingelheim$685
  • Lilly USA, LLC$656
  • plus $3K from 36 others

What the payments were for

  • Consulting fees$1,22011%
  • Speaking & faculty fees$9969%
  • Travel & lodging$2763%
  • Food & beverage$8,26777%
  • Education$60%
  • Gifts$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,790 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$184,515
Medicare patients
307
Services billed
3,498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide150$166,668
JardianceEmpagliflozin147$108,842
MounjaroTirzepatide72$75,100
TrulicityDulaglutide51$68,716
FarxigaDapagliflozin Propanediol47$45,744
RybelsusSemaglutide32$43,984
LinzessLinaclotide45$41,016
JanuviaSitagliptin Phosphate32$29,614
Nurtec OdtRimegepant Sulfate19$24,802
EliquisApixaban37$21,517
Tresiba Flextouch U-200Insulin Degludec18$21,007
Janumet XrSitagliptin Phos/Metformin Hcl12$14,672
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$14,646
MyrbetriqMirabegron15$12,385
Breo ElliptaFluticasone/Vilanterol27$11,510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,528$210,651182 claims
Lilly USA, LLCMounjaro, Trulicity$656$143,816123 claims
Boehringer IngelheimJardiance, Tradjenta$685$114,116160 claims
MerckJanuvia, Janumet Xr, Belsomra$184$51,04759 claims
AstraZenecaFarxiga, Symbicort$1,406$50,17366 claims
PfizerNurtec Odt, Eliquis, Dilantin$276$48,97673 claims
AbbVieLinzess$1,752$41,01645 claims
GSKBreo Ellipta, Incruse Ellipta$231$21,59756 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Angelo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →